You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

AZILECT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Azilect, and when can generic versions of Azilect launch?

Azilect is a drug marketed by Teva and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-six patent family members in eighteen countries.

The generic ingredient in AZILECT is rasagiline mesylate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Azilect

A generic version of AZILECT was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.

  Try a Trial

Summary for AZILECT
Drug patent expirations by year for AZILECT
Drug Prices for AZILECT

See drug prices for AZILECT

Recent Clinical Trials for AZILECT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2
University of FloridaPhase 2
Thomas Guttuso

See all AZILECT clinical trials

Pharmacology for AZILECT
Anatomical Therapeutic Chemical (ATC) Classes for AZILECT

US Patents and Regulatory Information for AZILECT

AZILECT is protected by two US patents.

Patents protecting AZILECT

Rasagiline formulations and processes for their preparation
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Rasagiline formulations of improved content uniformity
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PARKINSON'S DISEASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AZILECT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ⤷  Try a Trial ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 ⤷  Try a Trial ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ⤷  Try a Trial ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ⤷  Try a Trial ⤷  Try a Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for AZILECT

See the table below for patents covering AZILECT around the world.

Country Patent Number Title Estimated Expiration
Estonia 9700310 ⤷  Try a Trial
Poland 323470 ⤷  Try a Trial
Ukraine 88186 РАСАГИЛИНОВЫЕ ФОРМУЛЯЦИИ С УЛУЧШЕННОЙ ОДНОРОДНОСТЬЮ СОДЕРЖИМОГО;РАСАГІЛІНОВІ ФОРМУЛЯЦІЇ З ПОЛІПШЕНОЮ ОДНОРІДНІСТЮ ВМІСТУ (RASAGILINE FORMULATIONS OF IMPROVED CONTENT UNIFORMITY) ⤷  Try a Trial
South Korea 20170023211 함량 균일성이 개선된 라사길린 제형 (RASAGILINE FORMULATIONS OF IMPROVED CONTENT UNIFORMITY) ⤷  Try a Trial
South Africa 9408013 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AZILECT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0812190 SPC024/2005 Ireland ⤷  Try a Trial SPC024/2005, 20060725, EXPIRES: 20191011
0812190 91191 Luxembourg ⤷  Try a Trial 91191, EXPIRES: 20191012
0436492 CA 2005 00040 Denmark ⤷  Try a Trial
0812190 300205 Netherlands ⤷  Try a Trial 300205, 20141012, EXPIRES: 20191011
0812190 SPC/GB05/042 United Kingdom ⤷  Try a Trial PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.